RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its participation in the Series C financing round of Obsidian Therapeutics, Inc. The round successfully raised $160.5 million, a testament to the high growth potential seen in Obsidian’s innovative approaches to […]
OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]
